Aims: It was reported that exenatide ameliorated renal injury in diabetic rats. The present study was carried out to evaluate the effect of exenatide on 24-hour urinary albumin, urinary transforming growth factor-β1 (TGF-β1) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Methods: 31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks. Body mass index (BMI), fasting plasma glucose, 2-hour postprandial plasma glucose, glycated hemoglobin A1c, systolic blood pressure, diastolic blood pressure, 24-hour urinary albumin, urinary TGF-β1 and type IV collagen concentration were analyzed between the two treatment groups. 20 age- and BMI-matched healthy subjects were chosen as the normal control group (group NC, n = 20). Results: After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β1 and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups. Conclusions: Our results indicate that exenatide reduces urinary TGF-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria, which may be partly contributory to its directly renoprotective role.

Stamm C, Burnier M, Zanchi A: Diabetes and end stage renal disease. Eight year progression in the Canton de Vaud, Switzerland. Rev Med Suisse 2011;7:495–499.
Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J, China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090–1101.
Lawal M: Management of diabetes mellitus in clinical practice. Br J Nurs 2008;17:1106–1113.
Agarwal R: Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006;290:F600–F605.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post-hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540–1546.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
Metwally SS, Mosaad YM, Nassr AA, Zaki OM: Transforming growth factor-β1 in diabetic nephropathy. Egypt J Immunol 2005;12:103–112.
Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004;15(suppl):S55–S57.
Thorens B: Expression cloning of the pancreatic β-cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992;89:8641–8645.
Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968–2978.
Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965–978.
Kedees MH, Grigoryan M, Guz Y, Teitelman G: Differential expression of glucagon and glucagon-like peptide-1 receptors in mouse pancreatic α and β cells in two models of α-cell hyperplasia. Mol Cell Endocrinol 2009;311:69–76.
Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS: Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007;18:1227–1238.
Obata K, Iwata K, Ichida T, Inoue K, Matsumoto E, Muragaki Y, Ooshima A: One-step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chim Acta 1989;181:293–303.
Sthaneshwar P, Chan SP: Urinary type IV collagen levels in diabetes mellitus. Malays J Pathol 2010;32:43–47.
Eng J: Exendin peptides. Mt Sinai J Med 1992;59:147–149.
Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R, Reedtz-Runge S: Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem 2010;285:723–730.
Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397–4408.
Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D: Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009;94:1843–1852.
DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC: Effects of exenatide plus rosiglitazone on β-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010;33:951–957.
Eknoyan G: Obesity, diabetes, and chronic kidney disease. Curr Diab Rep 2007;7:449–453.
Wiederkehr M, Toto R, Fenves AZ, Ram CV: Hypertension and the kidney. Semin Nephrol 2005;25:236–245.
Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T: Exendin-4 has an antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009;380:44–49.
Ellis D, Forrest KY, Erbey J, Orchard TJ: Urinary measurement of transforming growth factor-β and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 1998;44:950–956.
Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi SI: Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011;60:1271–1277.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.